Total trials
73
Active
9
Phase 3
14
Total enrollment
7,864
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Relacorilant 150 mg once daily | — | — | — | — | 2 | ||
| Nab-paclitaxel 80 mg/m^2 | — | — | — | — | 2 | ||
| Nab-paclitaxel 100 mg/m^2 | — | — | — | — | — | 1 | |
| Miricorilant | — | — | — | — | 7 | ||
| Relacorilant | — | — | — | 11 | |||
| Nab-paclitaxel | — | — | — | — | 3 | ||
| Dazucorilant | — | — | — | — | 3 | ||
| Bevacizumab 10 mg/kg | — | — | — | — | — | 1 | |
| Nenocorilant 200 mg | — | — | — | — | — | 1 | |
| Nenocorilant 300 mg | — | — | — | — | — | 1 | |
| Nenocorilant 400 mg | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Dazucorilant 300 mg | — | — | — | — | — | 1 | |
| Dazucorilant 150 mg | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 |
Next readouts
- 2025-03-24
- 2026-05
- 2026-08
- 2026-09
- 2026-09
- 2026-10
- 2026-10-30
- 2026-12
- 2027-09
Top conditions
- Healthy22
- Cushing's Syndrome7
- Nonalcoholic Steatohepatitis (NASH)6
- Hypercortisolism4
- Cushing Syndrome4
- Major Depressive Disorder4
- Healthy Adults3
- Psychotic Disorders3
Frequently asked questions about Corcept Therapeutics
- How many clinical trials does Corcept Therapeutics have on ClinicalTrials.gov?
- Corcept Therapeutics is listed as the lead sponsor on 73 clinical trials in ClinicalTrials.gov, 9 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Corcept Therapeutics's trials are in Phase 3?
- 14 of Corcept Therapeutics's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Corcept Therapeutics focus on?
- Corcept Therapeutics's most-studied conditions on ClinicalTrials.gov are Healthy, Cushing's Syndrome, Nonalcoholic Steatohepatitis (NASH), Hypercortisolism, Cushing Syndrome.
- When are Corcept Therapeutics's next clinical trial readouts?
- Corcept Therapeutics has 9 upcoming primary-completion readouts tracked here; the soonest is “Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer”, expected around 2025-03-24.